LCDD
LCDD
40 Analysis of DNA
The techniques of DNA analysis have undergone a revolution in the past two decades. This
revolution has enabled the complete sequencing of several bacterial genomes and detailed
investigations into the regulation of growth and differentiation. These tools will play an
increasingly important role in medical care (diagnosis) and the legal system (DNA fingerprinting) in
the future.
2.71 Prophase
In the cell cycle the transition from the G2 phase to the M phase is not a well defined process. The
chromatin slowly condenses into well defined chromosomes, which is duplicated in the S phase.
During the prophase the nucleoli disappear. The condensed and replicated chromosomes are made
up of two chromatids. On each chromatid is the specific DNA sequence known as a centromere. At
the end of the prophase process, the cytoplasmic microtubules which are part of the interphase
cytoskeleton disassemble and the mitotic bipolar spindle begins to form. The spindle consists of
microtubules and associated proteins attached to two separate poles. The spindle initially assembles
outside of the nucleus.
2.72 Prometaphase
Prometaphase starts abruptly with the nuclear envelope disintegrating into membrane vesicles which
are indistinguishable from endoplasmic reticulum. The mitotic spindle, which has been outside of
the nucleus, now enters the nuclear region. On each centromere specialized protein complexes
called kinetochore mature and attach to the spindle microtubules. The microtubules that are
attached to the kinetochore protein complexes are called kinetochore microtubules. The remaining
microtubules are polar microtubules while the microtubules which are outside of the spindle are
called astral microtubules. From each sister chromatids in each chromosome the kinetochore
microtubules extend in opposite directions, eventually causing the chromosomes to align in the
center of the spindle poles.
2.73 Metaphase
The chromosomes aligned in the center of the spindle poles by the tension applied to them by the
kinetochore microtubules. Each chromosome is held in place by the corresponding kinetochore
microtubule from each spindle pole.
2.74 Anaphase
This phase is triggered by a signal from the cell which causes the two attached microtubules on each
chromosome to separate. The chromatids are separated and pulled to each spindle pole. The
movement towards the spindle pole by the chromatids is accomplished by Anaphase A and
Anaphase B. In Anaphase A the chromatids are pulled to the spindle pole by the shortening of the
kinetochore microtubules. During Anaphase B the polar microtubules elongate which cause the two
spindle poles to separate from each other.
2.75 Telophase
During Telophase the chromatids reach the spindle poles. The kinetochore microtubules then
disappear, while the polar microtubules continue to elongate separating the spindle poles further.
During the elongation process a new nuclear envelope forms around the group of daughter
chromosomes. The chromosomes begin to expand from their condensed state. Once the nuclear
envelope is formed the nucleoli begin to reappear.
2.76 Cytokinesis
The Cytoplasm is divided by the process known as cleavage which begins during the anaphase.
During cleavage the cell membrane in the middle of the cell begins to draw together. This causes a
indention in the cell at the center separating the two new nuclei. The indention deepens until it
encounters the remains of the mitotic spindle. The remains of the mitotic spindle narrows and then
finally breaks leaving two separated cells.
6.0 Drugs
Drugs are chemical agents that are capable of interacting with cellular components to produce a
desired effect such as microbe killing. Examples of several broad classes of drugs that have known
mechanisms of action are presented here.
6.10 Antibiotics
Antibiotics are macromolecules that are produced by microorganisms that suppress the growth of
competing species or synthetic molecules that kill or inhibit microorganisms. The availability of
antibiotics for over 50 years has led to a great reduction in the number of deaths due to infectious
disease. The development of resistance to antibiotics has hampered the ability to effectively treat all
infections, but newer drugs and the use of multiple antibiotics have the capability of treating
infections from drug resistant microbes.
6.10.1 Aminoglycosides
Aminoglycosides are bactericidal antibiotics that halt translation by binding to the 30S ribosomal
subunit and inhibit the initiation step. If an aminoglycoside binds to a ribosome that has began
elongation, it will cause misreading of the remaining mRNA. These antibiotics are effective against
many gram negative organisms, and resistance arises from plasmids carrying
aminoglycoside-modifying enzymes. Since plasmids can rapidly spread through a microbial
population through conjugation and transformation, this represents a major public health concern.
Examples of aminoglycosides include streptomycin, kanamycin, gentamicin, neomycin, and
netilmicin. Streptomycin is illustrated below.
6.10.2 Tetracyclines
Tetracyclines have a broad spectrum of activity against gram negative and gram positive organisms.
It is also effective against both anaerobes and aerobes, with resistance developing from plasmid
encoded enzymes. These antibiotics are bacteriostatic and act by inhibiting translation by
competing with aminoacyl-tRNAs for the A site on the ribosome. Examples of tetracyclines include
tetracycline, demeclocycline, minocycline, and doxycycline. The structure of tetracycline is shown
below.
6.10.3 Chloramphenicol
Chloramphenicol is a potent antibiotic that inhibits translation in both bacterial and mammalian
cells. This drug binds to the 50S ribosomal subunit and inhibits the peptidyl transferase step in
protein synthesis. This drug is bacteriostatic and has a wide range of activity against many aerobic
and anaerobic organisms. Resistance usually develops through the acquisition of a plasmid
encoding for chloramphenicol acetyl transferase which inactivates the drug. Chloramphenicol is the
only drug of its class, and its use is limited because it is also capable of inhibiting mammalian
translation.
6.10.4 Quinolones
Quinolone antibiotics inhibit bacterial DNA gyrase, which is required to maintain a proper degree of
supercoiling in the DNA. These antibiotics bind to the gyrase and inhibit the strand nicking and
strand closing activities of the enzyme. Inhibition of DNA gyrase suppresses replication and
transcription. This is fatal to bacterial cells. These antibiotics have a broad spectrum of action
against aerobic bacteria, but resistance develops during prolonged administration due to mutations
within the bacterial DNA gyrase gene. Examples of quinolones include nalidixic acid, norfloxacin,
cinoxacin, ciprofloxacin, ofloxacin, sparfloxacin, lomefloxacin, fleroxacin, pefloxacin, and
amifloxacin.
6.10.4 Macrolides
Macrolides are bacteriostatic against gram positive bacteria. They bind to the 50S ribosomal
subunit and inhibit the translocation step and causing premature termination during transcription.
Resistance develops through mutation in the genes for the 50S ribosomal subunit. Examples of
macrolides include erythromycin, clarithromycin, and azithromycin. The structure of erythromycin
is shown below.
6.11.2 Zidovudine
Zidovudine, also known as AZT, is a thymidine nucleoside analog that inhibits retroviral
replication. This drug is phosphorylated by thymidine kinase to form a zidovudine monophosphate
which is converted to a zidovudine triphosphate. The zidovudine triphosphate can then be
incorporated into DNA, where it causes chain termination due to the lack of a 3’ OH group. This
drug also inhibits thymidylate kinase, which results in the depletion of the nucleotide pool in the
infected cell. Mutations in the viral reverse transcriptase can confer resistance to zidovudine.
6.12 Anticancer Drugs
Approximately 25% of the US population will be diagnosed with cancer in their lifetime, therefore
making cancer a very active area of research. Numerous drugs that attack cancer (and normal) cells
have been developed, mostly interfering with DNA and RNA synthesis. The major pitfall in this
approach is that all rapidly proliferating cells are affected, not just cancer cells.
6.12.1 Methotrexate
Methotrexate is a folic acid antimetabolite that acts by inhibiting dihydrofolate reductase, preventing
the formation of the coenzyme tetrahydrofolic acid. Deficiency of tetrahydrofolic acid inhibits one
carbon metabolism that is central to many cellular processes such as energy production, nucleotide
synthesis, and amino acid synthesis. The most pronounced inhibition of cellular metabolism occurs
during S-phase, making this drug useful against rapidly growing cancers such as lymphocytic
leukemia, breast cancer, and osteogenic carcinoma. Cancer cells can become resistant to
methotrexate by amplifying their dihydrofolate reductase genes or by reducing the expression of
membrane bound methotrexate transport proteins. Side effects include myelosuppression, rash,
alopecia, nausea, vomiting, and diarrhea. All of these effects are the result of the killing of rapidly
dividing cells such as those found in the intestinal tract.
6.12.2 6-Mercaptopurine
6-Mercaptopurine is a nucleoside analog that is converted to 6-mercaptopurine ribose phosphate
(6-MPRP). This nucleotide has a similar structure to AMP, and can therefore inhibit the committed
step of purine biosynthesis. Additionally 6-MPRP can be incorporated into DNA and RNA,
forming a strand of nucleic acid with an aberrant structure. 6-Mercaptopurine is used to maintain
remission for acute lymphoblastic leukemia. Resistance to 6-mercaptopurine is due to reduced
affinity by HGPRT for this substrate and increased metabolism of 6-mercaptopurine to thiouric acid.
Side effects include myelosuppression, rash, nausea, vomiting, hepatotoxicity, and diarrhea. All of
these effects are the result of the killing of rapidly dividing cells such as those found in the intestinal
tract.
6.12.5 Bleomycin
Bleomycin is a metal cheating glycopeptide that interacts with DNA to cause strand breakage after
oxidation from bleomycin-DNA-Fe(II) to bleomycin-Fe(III). This strand breakage can cause
chromosomal abnormalities and cell death. Bleomycin is used to treat testicular tumors and
squamous cell carcinomas. Resistance is mediated by uncharacterized detoxification enzymes and
increased drug efflux. Side effects include pulmonary toxicity, alopecia, and hyperpigmentation of
the hands. In contrast to many other anticancer drugs, bleomycin rarely causes myelosuppression.
6.12.6 Mechlorethamine
Mechlorethamine is a DNA-alkylating agent that is derived from mustard gas employed during
World War I. It crosslinks the N7 positions of guanine residues in DNA and can cause
depurination. This leads to an inhibition of DNA and RNA synthesis and can lead to strand breaks.
This anticancer agent is used to treat Hodgkin's disease and solid tumors. Resistance is mediated by
increased glutathione conjugation of the drug and decreased membrane permeability to the drug.
Side effects include nausea, vomiting, and pronounced immunosuppression.
7.01 Trisomy 21
Trisomy 21, or Down’s syndrome, affects about 1 child in 700 and is the result of chromosomal
nondisjunction during meiosis. The symptoms of this syndrome include mental retardation,
epicanthic folds, a higher frequency of congenital heart defects (40%), and occasionally a single
palmar crease. These defects are due to ‘extra’ copies of the genes found on chromosome 21, but
the exact mechanisms that produce the specific defects are not known.
7.01.1 Trisomy 18
Trisomy 18, or Edward's syndrome, affects about 1 child in 8000 and is the result of chromosomal
nondisjunction during meiosis. This syndrome consists of severe mental retardation, rocker bottom
feet, micrognathia, congenital heart defects, and a prominent occiput. Because of the number and
severity of the defects associated with trisomy 18, death usually occurs within the first year of life.
7.01.2 Trisomy 13
Trisomy 13, or Patau's syndrome, affects about 1 child in 6000 and is the result of chromosomal
nondisjunction during meiosis. This syndrome consists of severe mental retardation,
micropthalmial, microcephaly, cleft lip or palate, abnormal brain formation, congenital heart
defects, and polydactyly.
Because of the number and severity of the defects associated with trisomy 13, death usually occurs
within the first year of life.